ArticleMolecular cancer2025
NSUN2-mediated cytosine-5 methylation of FSP1 protects acute myeloid leukemia cells from ferroptosis.
Abstract read
In one paragraph
Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Article
- NSUN2-FOSB reciprocity facilitates leukemogenesis in an mHaematologica · 2026Article
- Tumor-intrinsic NSUN2 orchestrates immunosuppression in lung adenocarcinoma via the mExperimental hematology & oncology · 2026Article
- NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis.Respiratory research · 2026Article
- Epitranscriptomic control of cancer: the emerging roles of m⁵C and ac⁴C RNA modifications.Cell death discovery · 2026Review
- RNA modifications in cancer and their detection: a review.Japanese journal of clinical oncology · 2026Review
- RNA modifications and cancer ferroptosis.Cancer cell international · 2026Review
- Dickkopf 2 serves as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia targeted by evodiamine.Frontiers in medicine · 2026Article
- NSUN2-Mediated mInternational journal of general medicine · 2026Review
- Regulating Ferroptosis in Leukemic Stem Cells: From Stemness Preservation to Targeted Differentiation Strategies.Stem cell reviews and reports · 2026Review
- RNA Methylation in Cancer Metabolism: from Mechanisms to Therapeutic Opportunities.International journal of biological sciences · 2026Review
- Targeting STARD10 Alleviates Steatotic Liver Injury by Suppressing YBX1/ACSL1-Mediated Ferroptosis.International journal of biological sciences · 2026Article
- NOP2-mediated 5-methylcytosine Regulates Lipid Metabolism Reprogramming to Prime Tumors for Ferroptosis in Bladder Cancer Progression.International journal of biological sciences · 2026Article
- Ferroptosis in hematological malignancies: molecular mechanisms and therapeutic potential.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?Cell death & disease · 2025Review
- Mitochondria at the intersections of RNA modifications and metabolism reprogramming implications in cell death, tumor microenvironment, and immunotherapy.Journal of hematology & oncology · 2025Review
- Flaviviridae RdRp exploits NSUN2-driven m5C methylation to establish persistent infection.PLoS pathogens · 2025Article
- The Role of NSUN Family Genes in m5C Methylation and Diseases.Biomedicines · 2025Review
- The prognostic marker NRIP1 is associated with tumor progression and immune infiltration in acute myeloid leukemia.Acta biochimica et biophysica Sinica · 2025Article
- NSUN2 promotes leukemogenesis by ferritin heavy chain 1-mediated anti-ferroptosis and enhancing global protein synthesis in an mClinical epigenetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Wenle YeDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China.
Yanchun ZhaoDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China.
Yutong ZhouKey Laboratory of Hematopoietic Malignancies, Diagnosis and Treatment, Zhejiang Province, PR China.
Jiansong HuangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China.
Xiao HeResearch Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Zhixin MaWomen's Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China.
Xin HuangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China.
Chao HuDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China.
Fenglin LiKey Laboratory of Hematopoietic Malignancies, Diagnosis and Treatment, Zhejiang Province, PR China.
Qing LingDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China.
Huafeng WangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China.
Hongyan TongDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China.
Jie SunDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China. sunjiehm@zju.edu.cn.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China. jiej0503@zju.edu.cn.
Funding
China Postdoctoral Science Foundation No. 2024T170774National Natural Science Foundation of China No. 82170144, 82370163National Natural Science Foundation of China Youth Science Fund Project No. 82300173Research Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-2022034C
Abstract
RNA 5-methylcytosine (m
Indexed as
FerroptosisLeukemia, Myeloid, Acute5-MethylcytosineAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, LeukemicHumansMethylationMethyltransferasesMicePrognosisXenograft Model Antitumor Assays5-MethylcytosineMethyltransferasesNSUN2 protein, humanAcute myeloid leukemiaFerroptosisFerroptosis suppressor protein 1m5C modificationNOP2/Sun RNA methyltransferase 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.